Stockscreener 앱 받기
1.91
3.52%
0.065
시간 외 거래:
1.90
-0.01
-0.52%
Nkarta Inc 주식(NKTX)의 최신 뉴스
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Earnings on Thursday - Defense World
NKTX stock touches 52-week low at $1.69 amid market challenges - Investing.com
Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely? - Simply Wall St
Nkarta to Participate in March Investor Conferences - The Manila Times
NKTX stock touches 52-week low at $1.96 amid market challenges - Investing.com
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus
What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register
2.00%
자본화:
|
볼륨(24시간):